Genetic and Epigenetic Mechanisms of Developing Gestational Diabetes Mellitus and Its Effects on the Fetus: a Randomised Controlled Trial of Different Glycemic Targets During Pregnancy
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 850
- 试验地点
- 2
- 主要终点
- TRIB1
研究概览
简要总结
This is a randomized controlled trial of different glycemic targets during tratment of women with GDM with assessement of epygenetic aspects of their effects on the fetus and pregnancy outcomes. This study is interventional, randomised controlled trial, open-label.
详细描述
The study aims to clarify the effect of hyperglycemia and its correction, the level of physical activity and consumption of major macro- and micronutrients by women during pregnancy on DNA methylation and expression of genes involved in neuroendocrine regulation and development of metabolic diseases in offspring, as well as functional characteristics of human umbilical vein endothelial cells (HUVECs). For the purpose of the study women with GDM are randomised to 2 treatment groups per glycemic targets ( very tight and tight-moderate glycemic targets). Data on glycenmic levels during the study and consumption of major macro- and micronutrients will be collected using a mobile application with electronic dairies report forms.
This clinical trial record primarily describes the overarching observational cohort study "Genetic and Epigenetic Mechanisms of Developing Gestational Diabetes Mellitus and Its Effects on the Fetus" including women with GDM and healthy pregnant women.
Substudy Protocol: A key predefined component of this larger study is an interventional, randomized controlled substudy entitled "Tight versus less tight glycaemic targets for women with gestational diabetes mellitus: a randomised controlled trial" (also known as the GEM GDM Trial).
The GEM GDM Trial is an open-label, randomized controlled trial (RCT) that compares the effects of tight (very tight) versus less tight (tight-moderate) glycemic control on maternal and neonatal outcomes in women diagnosed with Gestational Diabetes Mellitus (GDM). Participants from the main GEM cohort who are diagnosed with GDM according to International Association of the Diabetes and Pregnancy Study Groups (IADPSG) criteria are eligible for screening and subsequent randomization into this substudy.
The substudy aims to enroll 650 pregnant women with a singleton pregnancy and GDM, randomly assigning them in a 1:1 ratio to one of two glycemic target groups.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Basic Science
- 盲法
- None (Investigator)
入排标准
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Pregnant women with GDM diagnosed according to the Russian national consensus and the recommendations of the International Association of Diabetes and Pregnancy Study Groups (fasting glucose of ≥5.1 mmol/L, and/or ≥10.0 mmol/L after 1 h, and/or ≥8.5 mmol/L after 2 h in oral glucose tolerance test (OGTT) with 75 g of glucose).
- •Gestational age at the time of inclusion in the study 12 weeks 0 days - 31 weeks 6 days
- •For control group: pregnant women with normal glucose tolerance confirmed by OGTT at 24-31 weeks of gestation.
排除标准
- •Diabetes mellitus type 1 and tipe 2
- •Other deseases that affect methabolism of carbohydrates
- •Use of drugs that affect methabolism of carbohydrates
- •Malformations of the fetus identifired prior to inclusion to the study.
结局指标
主要结局
TRIB1
时间窗: within 24 hours after delivery
Level of expression of TRIB1 gene
ANGPTL4
时间窗: within 24 hours after delivery
Level of expression of ANGPTL4 gene
NR3C1
时间窗: within 24 hours after delivery
Level of expression of NR3C1 gene
LEP
时间窗: within 24 hours after delivery
Level of expression of LEP gene
LGA newborns
时间窗: within 24 hours after delivery
Number (%) of large for gestational age (LGA) newborns
ADIPOQ
时间窗: within 24 hours after delivery
Level of expression of ADIPOQ gene
次要结局
- rate of preterm birth(delivery)
- gestational age(delivery)
- rate of neonatal hypoglycemia(first 48 hours of age)
- rate of neonatal respiratory distress syndrome(delivery)
- rate of jaundice(delivery)
- rate of NICU admission(within 72 hours postpartum)
- length of stay of infants admitted to neonatal intensive care unit(up to 30 days after delivery)
- cord blood C-peptide(delivery)
- rate of composite neonatal outcome(delivery)
- rate of maternal death(within 42 days of termination of pregnancy)
- rate of preeclampsia(from 20 weeks to delivery)
- rate of stroke(during pregnancy or within 42 days after delivery)
- rate of maternal respiratory arrest(During pregnancy or within 42 days after delivery)
- rate of maternal respiratory distress syndrome(During pregnancy or within 42 days after delivery)
- rate of maternal deep vein thrombosis or pulmonary embolus requiring anticoagulant therapy(During pregnancy or within 42 days after delivery)
- rate of maternal haemolysis(During pregnancy or within 42 days after delivery)
- Cesarian sections(within 24 hours after delivery)
- SGA newborns(within 24 hours after delivery)
- Methylation of candidate genes(within 24 hours after delivery)
- rate of macrosomia(delivery)
- birthweight(delivery)
- length at birth(delivery)
- rate of stillbirth(> 20 weeks)
- rate of neonatal death(1 month after delivery)
- rate of shoulder dystocia(delivery)
- rate of birth trauma(delivery)
- Cesarian sections(within 24 hours after delivery)
- SGA newborns(within 24 hours after delivery)
- Methylation of candidate genes(within 24 hours after delivery)
- rate of macrosomia(delivery)
- birthweight(delivery)
- length at birth(delivery)
- rate of stillbirth(> 20 weeks)
- rate of neonatal death(1 month after delivery)
- rate of shoulder dystocia(delivery)
- rate of neonatal hypoglycemia(first 48 hours of age)
- rate of neonatal respiratory distress syndrome(delivery)
- rate of jaundice(delivery)
- Rate of neonates with Apgar score <7 at 5 minutes(delivery)
- rate of NICU admission(within 72 hours postpartum)
- length of stay of infants admitted to neonatal intensive care unit(up to 30 days after delivery)
- cord blood C-peptide(delivery)
- rate of composite neonatal outcome(delivery)
- rate of maternal death(within 42 days of termination of pregnancy)
- rate of eclampsia(from 20 weeks to delivery)
- rate of placental abruption(before delivery)
- rate of birth trauma(delivery)
- rate of preterm birth(delivery)
- gestational age(delivery)
- rate of postpartum hemorrhage(delivery)
- rate of preeclampsia(from 20 weeks to delivery)
- rate of gestational hypertension(from 20 weeks to delivery)
- rate of induction of labor(delivery)
- rate of perineal trauma(delivery)
- rate of operative vaginal delivery (vacuum extraction)(delivery)
- gestational weight gain(delivery)
- blood pressure at admission to the birth unit(at admission to the birth unit)
- rate of maternal hypoglycemia(during pregnancy)
- insulin therapy requirements(from 12 weeks to delivery)
- rate of stroke(during pregnancy or within 42 days after delivery)
- rate of acute pulmonary oedema(During pregnancy of within 42 days after delivery)
- rate of cardiac arrest(During pregnancy or within 42 days after delivery)
- rate of maternal respiratory arrest(During pregnancy or within 42 days after delivery)
- rate of maternal respiratory distress syndrome(During pregnancy or within 42 days after delivery)
- rate of maternal deep vein thrombosis or pulmonary embolus requiring anticoagulant therapy(During pregnancy or within 42 days after delivery)
- rate of maternal haemolysis(During pregnancy or within 42 days after delivery)
